Tirzepatide alone reached 14.8% in the same trial. The catch: up to 27% of people on the combination quit over side effects, per the Motley Fool writeup.
Recap by typeshit. Full story at Yahoo Finance.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The Pharma Letter looks at whether semaglutide in pill form could stand in for weekly shots for people trying to lose weight.
Lilly's 80-week phase 3 study of 1,152 adults, published in The Lancet, also showed HbA1c drops. Diarrhea and nausea were more common than on placebo.
Loading…